Follow the people · Insider
John P. Schmid
John P. Schmid files insider transactions with the SEC as a director of BlossomHill Therapeutics (BLSM). We hold 2 disclosed purchases and sales filed since 5 November 2010, 1 of them in the last 90 days.
- Files forBLSM
- Disclosed buys and sells2 in all, 1 in the last 90 days
- Last disclosure10 August 2026
Positions held
10 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 10 August 2026 — 10 August 2026Director · BlossomHill Therapeutics (BLSM)1 Form 4 line · source: SEC Form 4
- Filed 24 February 2017 — 15 June 2026Director · Anaptysbio (ANAB)51 Form 4 lines · source: SEC Form 4
- Filed 20 April 2026 — 15 June 2026Director · First Tracks Biotherapeutics (TRAX)18 Form 4 lines · source: SEC Form 4
- Filed 25 March 2021 — 9 June 2026Director · Design Therapeutics (DSGN)8 Form 4 lines · source: SEC Form 4
- Filed 11 August 2025 — 11 August 2025Other role · BridgeBio Oncology Therapeutics (BBOT)2 Form 4 lines · source: SEC Form 4
- Filed 9 July 2020 — 8 January 2025Director · Poseida Therapeutics (PSTX)18 Form 4 lines · source: SEC Form 4
- Filed 27 February 2019 — 12 August 2024Director · Xeris Biopharma Holdings (XERS)22 Form 4 lines · source: SEC Form 4
- Filed 1 July 2016 — 19 March 2021Director · Neos Therapeutics (NEOS)11 Form 4 lines · source: SEC Form 4
- Filed 2 February 2015 — 5 May 2015Chief Financial Officer · Auspex Pharmaceuticals (ASPX)6 Form 4 lines · source: SEC Form 4
- Filed 3 November 2010 — 11 September 2013Chief Financial Officer · Trius Therapeutics (TSRX)34 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 6,000 shares of BlossomHill TherapeuticsSEC Form 410 August 2026Common Stock · traded 10 August 2026 · filed 10 August 2026
- exercised options over 6,030 shares of AnaptysbioSEC Form 417 June 2026Common Stock · traded 15 June 2026 · filed 17 June 2026
- exercised options over 6,030 shares of Anaptysbio (a derivative holding)SEC Form 417 June 2026Restricted Stock Unit · traded 15 June 2026 · filed 17 June 2026
- exercised options over 6,030 shares of First Tracks BiotherapeuticsSEC Form 417 June 2026Common Stock · traded 15 June 2026 · filed 17 June 2026
- exercised options over 6,030 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 417 June 2026Restricted Stock Unit · traded 15 June 2026 · filed 17 June 2026
- was granted 2,500 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 412 June 2026Restricted Stock Unit · traded 12 May 2026 · filed 12 June 2026
- was granted 7,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 412 June 2026Stock Option (right to buy) · traded 12 May 2026 · filed 12 June 2026
- was granted 30,000 shares of Design Therapeutics (a derivative holding)SEC Form 411 June 2026Stock Option (right to buy) · traded 9 June 2026 · filed 11 June 2026
- was granted 15,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 414 May 2026Restricted Stock Unit · traded 12 May 2026 · filed 14 May 2026
- was granted 42,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 414 May 2026Stock Option (right to buy) · traded 12 May 2026 · filed 14 May 2026
- was granted 15,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 5,500 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 6,030 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Restricted Stock Unit · traded 20 April 2026 · filed 22 April 2026
- was granted 4,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Restricted Stock Unit · traded 20 April 2026 · filed 22 April 2026
- was granted 6,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 6,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 11,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 11,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 9,200 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 10,600 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 16,510 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 16,510 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- returned to the issuer 15,000 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 11,000 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- returned to the issuer 9,200 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 9,200 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- returned to the issuer 10,600 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 10,600 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- returned to the issuer 16,510 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 16,510 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- returned to the issuer 16,510 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 16,510 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- returned to the issuer 5,500 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 15,000 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 5,500 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- returned to the issuer 6,000 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 6,000 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- returned to the issuer 6,000 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 6,000 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- returned to the issuer 11,000 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 11,000 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- returned to the issuer 11,000 shares of Anaptysbio (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- ▼ sold on the open market 12,596 shares of AnaptysbioSEC Form 41 April 2026Common Stock · traded 30 March 2026 · filed 1 April 2026
- ▼ sold on the open market 7,527 shares of AnaptysbioSEC Form 41 April 2026Common Stock · traded 30 March 2026 · filed 1 April 2026
- ▼ sold on the open market 522 shares of AnaptysbioSEC Form 41 April 2026Common Stock · traded 30 March 2026 · filed 1 April 2026
- was granted 5,500 shares of Anaptysbio (a derivative holding)SEC Form 48 January 2026Stock Option (right to buy) · traded 6 January 2026 · filed 8 January 2026
- was granted 4,000 shares of Anaptysbio (a derivative holding)SEC Form 48 January 2026Restricted Stock Unit · traded 6 January 2026 · filed 8 January 2026
- was granted 5,500 shares of Anaptysbio (a derivative holding)SEC Form 48 January 2026Stock Option (right to buy) · traded 6 January 2026 · filed 8 January 2026
- was granted 4,000 shares of Anaptysbio (a derivative holding)SEC Form 48 January 2026Restricted Stock Unit · traded 6 January 2026 · filed 8 January 2026
- acquired or disposed of, other 11,068 shares of AnaptysbioSEC Form 423 December 2025Common Stock · traded 23 December 2025 · filed 23 December 2025
- exercised options over 30,000 shares of BridgeBio Oncology Therapeutics (a derivative holding)SEC Form 411 August 2025Class B ordinary shares · traded 11 August 2025 · filed 11 August 2025
- exercised options over 30,000 shares of BridgeBio Oncology TherapeuticsSEC Form 411 August 2025Common Stock · traded 11 August 2025 · filed 11 August 2025
- exercised options over 6,030 shares of Anaptysbio (a derivative holding)SEC Form 417 June 2025Restricted Stock Unit · traded 15 June 2025 · filed 17 June 2025
- exercised options over 6,030 shares of AnaptysbioSEC Form 417 June 2025Common Stock · traded 15 June 2025 · filed 17 June 2025
- was granted 19,000 shares of Design Therapeutics (a derivative holding)SEC Form 412 June 2025Stock Option (right to buy) · traded 10 June 2025 · filed 12 June 2025
- acquired or disposed of, other 11,068 shares of AnaptysbioSEC Form 427 March 2025Common Stock · traded 25 March 2025 · filed 27 March 2025
- exercised options over 21,692 shares of Anaptysbio (a derivative holding)SEC Form 415 January 2025Stock Option (right to buy) · traded 13 January 2025 · filed 15 January 2025
- exercised options over 20,645 shares of Anaptysbio (a derivative holding)SEC Form 415 January 2025Stock Option (right to buy) · traded 13 January 2025 · filed 15 January 2025
- exercised options over 21,692 shares of AnaptysbioSEC Form 415 January 2025Common Stock · traded 13 January 2025 · filed 15 January 2025
- exercised options over 20,645 shares of AnaptysbioSEC Form 415 January 2025Common Stock · traded 13 January 2025 · filed 15 January 2025
- returned to the issuer 32,076 shares of Poseida Therapeutics (a derivative holding)SEC Form 48 January 2025Stock Option (Right to Buy) · traded 8 January 2025 · filed 8 January 2025
- returned to the issuer 16,038 shares of Poseida Therapeutics (a derivative holding)SEC Form 48 January 2025Stock Option (Right to Buy) · traded 8 January 2025 · filed 8 January 2025
- returned to the issuer 20,000 shares of Poseida Therapeutics (a derivative holding)SEC Form 48 January 2025Stock Option (Right to Buy) · traded 8 January 2025 · filed 8 January 2025
- returned to the issuer 20,000 shares of Poseida Therapeutics (a derivative holding)SEC Form 48 January 2025Stock Option (Right to Buy) · traded 8 January 2025 · filed 8 January 2025
- returned to the issuer 25,833 shares of Poseida Therapeutics (a derivative holding)SEC Form 48 January 2025Stock Option (Right to Buy) · traded 8 January 2025 · filed 8 January 2025
- returned to the issuer 28,500 shares of Poseida Therapeutics (a derivative holding)SEC Form 48 January 2025Stock Option (Right to Buy) · traded 8 January 2025 · filed 8 January 2025
- returned to the issuer 27,350 shares of Poseida Therapeutics (a derivative holding)SEC Form 48 January 2025Stock Option (Right to Buy) · traded 8 January 2025 · filed 8 January 2025
- returned to the issuer 27,350 shares of Poseida Therapeutics (a derivative holding)SEC Form 48 January 2025Stock Option (Right to Buy) · traded 8 January 2025 · filed 8 January 2025
- disposed of in a tender offer 58,950 shares of Poseida TherapeuticsSEC Form 48 January 2025Common Stock · traded 8 January 2025 · filed 8 January 2025
- was granted 16,510 shares of Anaptysbio (a derivative holding)SEC Form 47 January 2025Stock Option (right to buy) · traded 7 January 2025 · filed 7 January 2025
- was granted 6,030 shares of Anaptysbio (a derivative holding)SEC Form 47 January 2025Restricted Stock Unit · traded 7 January 2025 · filed 7 January 2025
- ▲ bought on the open market 4,515 shares of Xeris Biopharma HoldingsSEC Form 413 August 2024Common Stock · traded 12 August 2024 · filed 13 August 2024
- ▲ bought on the open market 4,285 shares of Xeris Biopharma HoldingsSEC Form 412 August 2024Common Stock · traded 9 August 2024 · filed 12 August 2024
- was granted 27,350 shares of Poseida Therapeutics (a derivative holding)SEC Form 418 June 2024Stock Option (Right to buy) · traded 17 June 2024 · filed 18 June 2024
- was granted 19,650 shares of Poseida TherapeuticsSEC Form 418 June 2024Common Stock · traded 17 June 2024 · filed 18 June 2024
- exercised options over 3,900 shares of Anaptysbio (a derivative holding)SEC Form 418 June 2024Restricted Stock Unit · traded 15 June 2024 · filed 18 June 2024
- exercised options over 3,900 shares of AnaptysbioSEC Form 418 June 2024Common Stock · traded 15 June 2024 · filed 18 June 2024
- was granted 19,000 shares of Design Therapeutics (a derivative holding)SEC Form 417 June 2024Stock Option (right to buy) · traded 13 June 2024 · filed 17 June 2024
- was granted 50,000 shares of Xeris Biopharma HoldingsSEC Form 45 June 2024Common Stock · traded 5 June 2024 · filed 5 June 2024
- ▲ bought on the open market 5,400 shares of Xeris Biopharma HoldingsSEC Form 410 May 2024Common Stock · traded 10 May 2024 · filed 10 May 2024
- ▲ bought on the open market 9,156 shares of Design TherapeuticsSEC Form 425 March 2024Common Stock · traded 22 March 2024 · filed 25 March 2024
- ▲ bought on the open market 17,809 shares of Design TherapeuticsSEC Form 425 March 2024Common Stock · traded 25 March 2024 · filed 25 March 2024
- ▲ bought on the open market 4,500 shares of Xeris Biopharma HoldingsSEC Form 414 March 2024Common Stock · traded 14 March 2024 · filed 14 March 2024
- was granted 16,510 shares of Anaptysbio (a derivative holding)SEC Form 45 January 2024Stock Option (right to buy) · traded 3 January 2024 · filed 5 January 2024
- was granted 6,030 shares of Anaptysbio (a derivative holding)SEC Form 45 January 2024Restricted Stock Unit · traded 3 January 2024 · filed 5 January 2024
- ▲ bought on the open market 6,500 shares of Xeris Biopharma HoldingsSEC Form 417 November 2023Common Stock · traded 16 November 2023 · filed 17 November 2023
- was granted 27,350 shares of Poseida Therapeutics (a derivative holding)SEC Form 416 June 2023Stock Option (Right to buy) · traded 15 June 2023 · filed 16 June 2023
- was granted 19,650 shares of Poseida TherapeuticsSEC Form 416 June 2023Common Stock · traded 15 June 2023 · filed 16 June 2023
- was granted 42,500 shares of Xeris Biopharma HoldingsSEC Form 47 June 2023Common Stock · traded 7 June 2023 · filed 7 June 2023
- was granted 15,000 shares of Design Therapeutics (a derivative holding)SEC Form 42 June 2023Stock Option (right to buy) · traded 31 May 2023 · filed 2 June 2023
- was granted 10,600 shares of Anaptysbio (a derivative holding)SEC Form 410 January 2023Stock Option (right to buy) · traded 6 January 2023 · filed 10 January 2023
- was granted 3,900 shares of Anaptysbio (a derivative holding)SEC Form 410 January 2023Restricted Stock Unit · traded 6 January 2023 · filed 10 January 2023
- was granted 15,000 shares of Design Therapeutics (a derivative holding)SEC Form 416 June 2022Stock Option (right to buy) · traded 15 June 2022 · filed 16 June 2022
- was granted 28,500 shares of Poseida Therapeutics (a derivative holding)SEC Form 416 June 2022Stock Option (Right to Buy) · traded 16 June 2022 · filed 16 June 2022
- was granted 19,650 shares of Poseida TherapeuticsSEC Form 416 June 2022Common Stock · traded 16 June 2022 · filed 16 June 2022
- was granted 25,000 shares of Xeris Biopharma Holdings (a derivative holding)SEC Form 49 June 2022Stock Option (Right to Buy) · traded 8 June 2022 · filed 9 June 2022
- was granted 15,000 shares of Xeris Biopharma HoldingsSEC Form 49 June 2022Common Stock · traded 8 June 2022 · filed 9 June 2022
- was granted 9,200 shares of Anaptysbio (a derivative holding)SEC Form 414 February 2022Stock Option (right to buy) · traded 10 February 2022 · filed 14 February 2022
- returned to the issuer 25,220 shares of Xeris Pharmaceuticals (a derivative holding)SEC Form 45 October 2021Stock Option (Right to Buy) · traded 5 October 2021 · filed 5 October 2021
- returned to the issuer 20,000 shares of Xeris Pharmaceuticals (a derivative holding)SEC Form 45 October 2021Stock Option (Right to Buy) · traded 5 October 2021 · filed 5 October 2021
- returned to the issuer 11,228 shares of Xeris Pharmaceuticals (a derivative holding)SEC Form 45 October 2021Stock Option (Right to Buy) · traded 5 October 2021 · filed 5 October 2021
- returned to the issuer 11,228 shares of Xeris Pharmaceuticals (a derivative holding)SEC Form 45 October 2021Stock Option (Right to Buy) · traded 5 October 2021 · filed 5 October 2021
- returned to the issuer 5,659 shares of Xeris PharmaceuticalsSEC Form 45 October 2021Common Stock · traded 5 October 2021 · filed 5 October 2021
- was granted 25,220 shares of Xeris Biopharma Holdings (a derivative holding)SEC Form 45 October 2021Stock Option (Right to Buy) · traded 5 October 2021 · filed 5 October 2021
- was granted 20,000 shares of Xeris Biopharma Holdings (a derivative holding)SEC Form 45 October 2021Stock Option (Right to Buy) · traded 5 October 2021 · filed 5 October 2021
- was granted 11,228 shares of Xeris Biopharma Holdings (a derivative holding)SEC Form 45 October 2021Stock Option (Right to Buy) · traded 5 October 2021 · filed 5 October 2021
- was granted 11,228 shares of Xeris Biopharma Holdings (a derivative holding)SEC Form 45 October 2021Stock Option (Right to Buy) · traded 5 October 2021 · filed 5 October 2021
- was granted 5,659 shares of Xeris Biopharma HoldingsSEC Form 45 October 2021Common Stock · traded 5 October 2021 · filed 5 October 2021
- was granted 25,833 shares of Poseida Therapeutics (a derivative holding)SEC Form 426 July 2021Stock Option (Right to Buy) · traded 23 July 2021 · filed 26 July 2021
- was granted 20,000 shares of Poseida Therapeutics (a derivative holding)SEC Form 417 June 2021Stock Option (Right to Buy) · traded 16 June 2021 · filed 17 June 2021
- was granted 11,228 shares of Xeris Pharmaceuticals (a derivative holding)SEC Form 48 June 2021Stock Option (Right to Buy) · traded 8 June 2021 · filed 8 June 2021
- was granted 15,000 shares of Design Therapeutics (a derivative holding)SEC Form 429 March 2021Stock Option (right to buy) · traded 25 March 2021 · filed 29 March 2021
- returned to the issuer 23,453 shares of Neos TherapeuticsSEC Form 419 March 2021Common Stock · traded 19 March 2021 · filed 19 March 2021
- returned to the issuer 12,500 shares of Neos Therapeutics (a derivative holding)SEC Form 419 March 2021Stock Option (Right to Buy) · traded 19 March 2021 · filed 19 March 2021
- returned to the issuer 14,777 shares of Neos Therapeutics (a derivative holding)SEC Form 419 March 2021Stock Option (Right to Buy) · traded 19 March 2021 · filed 19 March 2021
- returned to the issuer 18,322 shares of Neos Therapeutics (a derivative holding)SEC Form 419 March 2021Stock Option (Right to Buy) · traded 19 March 2021 · filed 19 March 2021
- returned to the issuer 22,756 shares of Neos Therapeutics (a derivative holding)SEC Form 419 March 2021Stock Option (Right to Buy) · traded 19 March 2021 · filed 19 March 2021
- returned to the issuer 46,907 shares of Neos Therapeutics (a derivative holding)SEC Form 419 March 2021Stock Option (Right to Buy) · traded 19 March 2021 · filed 19 March 2021
- was granted 11,000 shares of Anaptysbio (a derivative holding)SEC Form 412 February 2021Stock Option (right to buy) · traded 10 February 2021 · filed 12 February 2021
- was granted 20,000 shares of Poseida Therapeutics (a derivative holding)SEC Form 413 July 2020Stock Option (Right to Buy) · traded 9 July 2020 · filed 13 July 2020
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.